BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 28158970)

  • 1. Tumor necrosis factor alpha inhibitors have no effect on a human T-lymphotropic virus type-I (HTLV-I)-infected cell line from patients with HTLV-I-associated myelopathy.
    Fukui S; Nakamura H; Takahashi Y; Iwamoto N; Hasegawa H; Yanagihara K; Nakamura T; Okayama A; Kawakami A
    BMC Immunol; 2017 Feb; 18(1):7. PubMed ID: 28158970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of anti-tumor necrosis factor biologics in the treatment of rheumatoid arthritis does not change human T-lymphotropic virus type 1 markers: a case series.
    Umekita K; Umeki K; Miyauchi S; Ueno S; Kubo K; Kusumoto N; Takajo I; Nagatomo Y; Okayama A
    Mod Rheumatol; 2015 Sep; 25(5):794-7. PubMed ID: 24252020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High IFN-γ/IL-10 expression ratio and increased frequency of persistent human T-cell lymphotropic virus type 1-infected clones are associated with human T-cell lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis development.
    Espíndola OM; Oliveira LC; Ferreira PM; Leite AC; Lima MA; Andrada-Serpa MJ
    Intervirology; 2015; 58(2):106-14. PubMed ID: 25833232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance to tumor necrosis factor-alpha-induced apoptosis in human T-lymphotropic virus type I-infected T cell lines.
    Yang YC; Hsu TY; Lin RH; Su IJ; Chen JY; Yang CS
    AIDS Res Hum Retroviruses; 2002 Feb; 18(3):207-12. PubMed ID: 11839155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disulfide-mediated apoptosis of human T-lymphotrophc virus type-I (HTLV-I)-infected cells in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis.
    Nishiura Y; Nakamura T; Fukushima N; Nakamura H; Ida H; Aramaki T; Eguchi K
    Antivir Ther; 2009; 14(4):533-42. PubMed ID: 19578238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with anti–tumor necrosis factor biologic agents in human T lymphotropic virus type I–positive patients with rheumatoid arthritis.
    Umekita K; Hidaka T; Miyauchi S; Ueno S; Kubo K; Takajo I; Hashiba Y; Kai Y; Nagatomo Y; Okayama A
    Arthritis Care Res (Hoboken); 2014 May; 66(5):788-92. PubMed ID: 24127184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involvement of p38 MAPK signaling pathway in IFN-gamma and HTLV-I expression in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis.
    Fukushima N; Nishiura Y; Nakamura T; Yamada Y; Kohno S; Eguchi K
    J Neuroimmunol; 2005 Feb; 159(1-2):196-202. PubMed ID: 15652420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brief Report: Attenuated Effectiveness of Tumor Necrosis Factor Inhibitors for Anti-Human T Lymphotropic Virus Type I Antibody-Positive Rheumatoid Arthritis.
    Suzuki T; Fukui S; Umekita K; Miyamoto J; Umeda M; Nishino A; Okada A; Koga T; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Fujikawa K; Aramaki T; Mizokami A; Matsuoka N; Ueki Y; Eguchi K; Sato S; Hidaka T; Origuchi T; Okayama A; Kawakami A; Nakamura H
    Arthritis Rheumatol; 2018 Jul; 70(7):1014-1021. PubMed ID: 29471588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tocilizumab has no direct effect on cell lines infected with human T-cell leukemia virus type 1.
    Endo Y; Fukui S; Koga T; Sasaki D; Hasegawa H; Yanagihara K; Okayama A; Nakamura T; Kawakami A; Nakamura H
    J Int Med Res; 2021 Mar; 49(3):3000605211002083. PubMed ID: 33745335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour necrosis factor α antagonists in the treatment of rheumatoid arthritis: an immunological perspective.
    Meroni PL; Valesini G
    BioDrugs; 2014 Apr; 28 Suppl 1():S5-13. PubMed ID: 24687234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of T Regulatory Lymphocytes Transcription Factors in HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) Patients.
    Ghezeldasht SA; Sadeghian H; Azarpazhooh MR; Shamsian SAA; Rafatpanah H; Mahmoodi M; Rezaee SA
    Appl Biochem Biotechnol; 2017 Aug; 182(4):1403-1414. PubMed ID: 28101786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Demonstration of human T lymphotropic virus type I (HTLV-I) tax-specific CD8+ lymphocytes directly in peripheral blood of HTLV-I-associated myelopathy/tropical spastic paraparesis patients by intracellular cytokine detection.
    Kubota R; Kawanishi T; Matsubara H; Manns A; Jacobson S
    J Immunol; 1998 Jul; 161(1):482-8. PubMed ID: 9647259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different cytokine production in tax-expressing cells between patients with human T cell lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis and asymptomatic HTLV-I carriers.
    Furukawa Y; Saito M; Matsumoto W; Usuku K; Tanaka Y; Izumo S; Osame M
    J Infect Dis; 2003 Apr; 187(7):1116-25. PubMed ID: 12660926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of FAP-1 (Fas-associated phosphatase) and resistance to Fas-mediated apoptosis in T cell lines derived from human T cell leukemia virus type 1-associated myelopathy/tropical spastic paraparesis patients.
    Arai M; Kannagi M; Matsuoka M; Sato T; Yamamoto N; Fujii M
    AIDS Res Hum Retroviruses; 1998 Feb; 14(3):261-7. PubMed ID: 9491917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased HTLV type 1 tax specific CD8+ cells in HTLV type 1-asociated myelopathy/tropical spastic paraparesis: correlation with HTLV type 1 proviral load.
    Kubota R; Nagai M; Kawanishi T; Osame M; Jacobson S
    AIDS Res Hum Retroviruses; 2000 Nov; 16(16):1705-9. PubMed ID: 11080814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased human T lymphotropic virus type I (HTLV-I) provirus load and alteration in T cell phenotype after interferon-alpha therapy for HTLV-I-associated myelopathy/tropical spastic paraparesis.
    Saito M; Nakagawa M; Kaseda S; Matsuzaki T; Jonosono M; Eiraku N; Kubota R; Takenouchi N; Nagai M; Furukawa Y; Usuku K; Izumo S; Osame M
    J Infect Dis; 2004 Jan; 189(1):29-40. PubMed ID: 14702150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immunopathogenesis and treatment of the myelopathy associated to the HTLV-I virus].
    Carod-Artal FJ
    Rev Neurol; 2009 Feb 1-15; 48(3):147-55. PubMed ID: 19206063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered expression of degranulation-related genes in CD8+ T cells in human T lymphotropic virus type I infection.
    Malta TM; Silva IT; Pinheiro DG; Santos AR; Pinto MT; Panepucci RA; Takayanagui OM; Tanaka Y; Covas DT; Kashima S
    AIDS Res Hum Retroviruses; 2013 May; 29(5):826-36. PubMed ID: 23301858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proviral load and the balance of serum cytokines in HTLV-1-asymptomatic infection and in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP).
    Starling AL; Martins-Filho OA; Lambertucci JR; Labanca L; de Souza Pereira SR; Teixeira-Carvalho A; Martins ML; Ribas JG; Carneiro-Proietti AB; Gonçalves DU
    Acta Trop; 2013 Jan; 125(1):75-81. PubMed ID: 23022356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-Tax antibody levels in asymptomatic carriers, oligosymptomatic carriers, patients with rheumatologic disease or with HAM/TSP do not correlate with HTLV-1 proviral load.
    de Souza JG; da Fonseca FG; Martins ML; Martins CP; de Carvalho LD; Coelho-dos-Reis JG; Carneiro-Proietti AB; Martins-Filho OA; Barbosa-Stancioli EF;
    J Clin Virol; 2011 Jan; 50(1):13-8. PubMed ID: 20951636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.